Terminated PHASE1 INTERVENTIONAL 2-arm NCT05366439

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge Model

Sponsor: Atea Pharmaceuticals, Inc.

Conditions Dengue

Interventions AT-752 Placebo Comparator

Updated 4 times since 2022 Last updated: Apr 20, 2023 Started: Apr 22, 2022 Primary completion: Mar 16, 2023 Completion: Mar 16, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision to deprioritize the dengue program

Other terminated trials from Atea Pharmaceuticals, Inc.

More terminations from Atea Pharmaceuticals, Inc.

This PHASE1 trial investigates Dengue and is currently terminated or withdrawn. Atea Pharmaceuticals, Inc. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
May 2023 — Jul 2024 [monthly]

Terminated PHASE1

Status: Recruiting → Terminated
Jun 2022 — May 2023 [monthly]

Recruiting PHASE1

First recorded

Apr 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Atea Pharmaceuticals, Inc.

Data source: Atea Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Syracuse, United States